BMS

CheckMate 848

NCT03668119

JCP052

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848)

Status:

Closed to Accrual

26459-200.png

II

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

TBM-H

Investigational

Product

Ipilimumab

Treatment Arms

o Experimental: Nivolumab + Ipilimumab Combination

o Experimental: Nivolumab Monotherapy